GlassScriptPhysician profile
Stephen Michael Padgett
NPI 1639531130
$4,153.38
in general payments reported to CMS, 2019-2025
23 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $233 · 2021: $493 · 2022: $2,164 · 2023: $508 · 2024: $367 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,164 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,163.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medical Device Business Services, INC. | $1,463.74 | 2022 | |
| Astellas Pharma US INC | $615.58 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $462.41 | 2020-2024 | |
| Abbvie INC. | $435.02 | 2020-2023 | |
| Ethicon US, LLC | $243.95 | 2022-2024 | Stratafix |
| Amgen INC. | $236.30 | 2021-2025 | Evenity, Prolia, Prolia |
| Baxter Healthcare | $121.83 | 2020 | |
| Mayne Pharma Commercial LLC | $83.64 | 2021-2025 | |
| Therapeuticsmd, INC. | $76.23 | 2020-2022 | |
| Avion Pharmaceuticals | $68.54 | 2020-2022 | |
| Exeltis, USA INC. | $57.39 | 2021-2023 | Slynd |
| Millicent US INC | $52.90 | 2024-2025 | Femlyv, Femring, Intrarosa |
| Mylan Pharmaceuticals INC. | $39.11 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.48 | 2022 | |
| Hologic Sales and Service, LLC | $31.52 | 2024 | Myosure Tissue Removal Device, Omni Hysteroscope |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $29.73 | 2024 | Quviviq |
| Becton, Dickinson and Company | $20.00 | 2025 | Bd Onclarity |
| Myovant Sciences INC. | $17.30 | 2021 | |
| Lilly USA, LLC | $15.03 | 2021 | |
| Sanara Medtech INC. | $14.88 | 2022 | |
| Novo Nordisk INC | $14.24 | 2022 | |
| Evofem Biosciences, INC. | $12.69 | 2021 | |
| Organon LLC | $7.87 | 2023 | Jada System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Padgett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.